PRIMIDONE
Clinical safety rating: avoid
Positive evidence of fetus risks but benefits may outweigh risks in some cases
Primidone is a barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and neuronal inhibition. It also has active metabolites, phenobarbital and phenylethylmalonamide, which contribute to anticonvulsant effects.
| Metabolism | Primidone is metabolized primarily in the liver via CYP450 enzymes, mainly CYP2C9 and CYP2C19, to active metabolites phenobarbital and phenylethylmalonamide. |
| Excretion | Renal: approximately 40% unchanged, 30% as phenobarbital, 20% as phenylethylmalonamide (PEMA); fecal: <5% |
| Half-life | Primidone: 10-12 hours; phenobarbital metabolite: 48-120 hours; PEMA: 16-18 hours. Steady-state requires 4-7 days for primidone but up to 2-3 weeks for phenobarbital accumulation. |
| Protein binding | Primidone: 20-30% bound to albumin; phenobarbital: 45-50% bound to albumin. |
| Volume of Distribution | Primidone: 0.6-1.0 L/kg; distributes widely, crosses blood-brain barrier and placenta. |
| Bioavailability | Oral: 90-100% (immediate-release tablets); food slightly delays absorption but does not affect extent. |
| Onset of Action | Oral: 30-60 minutes for seizure protection; IV not available; parenteral routes not clinically used. |
| Duration of Action | Oral: 6-8 hours for primidone; accumulation of phenobarbital extends effective duration to 12-24 hours with repeated dosing. |
| Molecular Weight | 218.26 |
Initial: 100-125 mg orally at bedtime for 3 days; increase to 100-125 mg twice daily for 3 days, then 100-125 mg three times daily for 3 days; maintenance: 250 mg three times daily. Maximum: 500 mg four times daily.
| Dosage form | TABLET |
| Renal impairment | CrCl 30-49 mL/min: administer q8h. CrCl 10-29 mL/min: administer q12h. CrCl <10 mL/min: administer q24h. Dialyzable: yes; supplement 30% of dose post-hemodialysis. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25-50%. Child-Pugh C: reduce dose by 50% or avoid use. |
| Pediatric use | Initial: 2-3 mg/kg/day divided q8h, increase over 2 weeks to 10-25 mg/kg/day divided q8h. Maximum: 1 g/day in 2-3 divided doses. |
| Geriatric use | Initiate at 100-125 mg/day; increase slowly (every 3-5 days) by 100-125 mg increments; monitor for sedation, ataxia, and cognitive impairment. |
| 1st trimester | Associated with increased risk of major congenital malformations including facial clefts, cardiac defects, and neural tube defects. Risk of hemorrhagic disease of the newborn due to vitamin K deficiency. |
| 2nd trimester | May cause growth retardation and minor anomalies. Continued risk of bleeding complications; monitor prothrombin time and consider vitamin K supplementation. |
| 3rd trimester | Risk of neonatal hemorrhage, withdrawal symptoms, and sedation. Monitor newborn for bleeding and respiratory depression. |
Clinical note
CNS depressants may enhance sedative effects Can cause sedation and megaloblastic anemia.
| Placental transfer | Primidone crosses the placenta extensively, achieving fetal plasma concentrations similar to maternal levels. Phenobarbital, its active metabolite, also readily crosses, resulting in fetal accumulation. |
| Breastfeeding | Primidone and its metabolites (phenobarbital and PEMA) are excreted into breast milk with a milk:plasma ratio of 0.4-0.7. Reported infant serum levels can reach therapeutic range, causing sedation and feeding difficulties. The American Academy of Pediatrics considers it a drug of concern; alternatives should be considered unless benefits outweigh risks. |
■ FDA Black Box Warning
Primidone may be habit forming. Tolerance and psychological and physical dependence may occur with prolonged use. Withdrawal symptoms may occur following abrupt discontinuation and can be severe or fatal. Use with caution in patients with a history of drug or alcohol abuse.
| Common Effects | Sedation |
| Serious Effects |
Hypersensitivity to primidone or phenobarbitalPorphyria (may induce porphyrin synthesis)Severe hepatic impairmentSevere respiratory depression
| Precautions | Risk of respiratory depression, particularly with high doses or when combined with other CNS depressants. Caution in patients with hepatic or renal impairment, porphyria, or history of substance abuse. Avoid abrupt withdrawal to prevent precipitating status epilepticus. |
| Food/Dietary |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) if used with caution; monitor infant for sedation and weight gain. Alternatively rated 'Avoid' in some guidelines due to prolonged half-life in neonates. |
| Teratogenic Risk | Pregnancy Category D. First trimester: Increased risk of major malformations, particularly neural tube defects, cleft lip/palate, and cardiac anomalies, attributed to folic acid antagonism. Second/third trimester: Continued risk of growth restriction, dysmorphic features, and cognitive impairment. Neonatal hemorrhage due to vitamin K deficiency and withdrawal syndrome (hyperexcitability, seizures) may occur. |
| Fetal Monitoring | Preconception: Folic acid supplementation (4-5 mg/day) to reduce neural tube defect risk. During pregnancy: Serial ultrasound for fetal growth and anatomy; maternal serum alpha-fetoprotein (MSAFP) screening or amniocentesis for neural tube defects; assess vitamin K levels and administer phytomenadione to neonate at birth. Monitor maternal anticonvulsant levels (free primidone and phenobarbital) due to pregnancy-induced pharmacokinetic changes. |
| Fertility Effects | Primidone may affect fertility through enzyme induction, potentially altering sex hormone metabolism and menstrual cyclicity. Limited human data; animal studies show no significant direct impairment. Caution in women with preexisting reproductive disorders. |
| Avoid alcohol. No specific food interactions, but take with food if GI upset occurs. Maintain adequate vitamin D and calcium intake due to risk of osteomalacia. |
| Clinical Pearls | Primidone is metabolized to phenobarbital and phenylethylmalonamide; monitor serum levels of both. Start low (50-100 mg/day) and titrate slowly to avoid sedation. Abrupt withdrawal can precipitate status epilepticus. Use with caution in porphyria due to hepatic enzyme induction. |
| Patient Advice | Take exactly as prescribed; do not stop suddenly without medical advice. · Avoid alcohol and other CNS depressants; may cause dizziness or drowsiness. · Report any rash, fever, or unusual bleeding/bruising immediately. · May decrease effectiveness of oral contraceptives; use additional contraception. · May cause vitamin D and folate deficiency; consider supplementation with long-term use. |